On Wednesday, Gilead announced that it was licensing an HIV development program drug from Boehringer Ingelheim. The deal includes BI 224436, which has been tested in a phase 1 trial already and follow-on compounds in the same class.
The drugs target the same protein as Merck's
Boehringer Ingelheim has been striking deals with American drugmakers recently. Earlier this year, the company paired up with Eli Lilly
The partnership comes with standard upfront, milestone, and royalty payments, but the details weren't disclosed. The company got a better deal with Johnson & Johnson
Of course, nothing will beat the quad, which Gilead owns in its entirety. Gilead may not be resting on its laurels, but the approval and sales of the Quad are still the most important near-term issues for Gilead.
Fool contributor Brian Orelli holds no position in any company mentioned. Check out his holdings and a short bio. The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services have recommended buying shares of Johnson & Johnson and Gilead Sciences and creating a diagonal call position in Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.